Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Danazol for pelvic pain associated with endometriosis.
Selak V, Farquhar C, Prentice A, Singla A. Selak V, et al. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000068. doi: 10.1002/14651858.CD000068.pub2. Cochrane Database Syst Rev. 2007. PMID: 17943735 Review.
Danazol for pelvic pain associated with endometriosis.
Selak V, Farquhar C, Prentice A, Singla A. Selak V, et al. Cochrane Database Syst Rev. 2000;(2):CD000068. doi: 10.1002/14651858.CD000068. Cochrane Database Syst Rev. 2000. PMID: 10796483 Updated. Review.
Danazol for pelvic pain associated with endometriosis.
Selak V, Farquhar C, Prentice A, Singla A. Selak V, et al. Cochrane Database Syst Rev. 2001;(4):CD000068. doi: 10.1002/14651858.CD000068. Cochrane Database Syst Rev. 2001. PMID: 11687066 Updated. Review.
Aspirin for primary prevention: yes or no?
Selak V, Elley CR, Wells S, Rodgers A, Sharpe N. Selak V, et al. J Prim Health Care. 2010 Jun;2(2):92-9. J Prim Health Care. 2010. PMID: 20690297
Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.
Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, Arroll B, Bots ML, Brown A, Crengle S, Dorairaj P, Elley CR, Grobbee DE, Harwood M, Hillis GS, Laba TL, Neal B, Peiris D, Rafter N, Reid C, Stanton A, Tonkin A, Usherwood T, Wadham A, Rodgers A. Selak V, et al. Heart. 2019 Jan;105(1):42-48. doi: 10.1136/heartjnl-2018-313108. Epub 2018 Jun 28. Heart. 2019. PMID: 29954855
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A. Selak V, et al. BMJ. 2014 May 27;348:g3318. doi: 10.1136/bmj.g3318. BMJ. 2014. PMID: 24868083 Clinical Trial.
Adherence for each drug type at 12 months was high in both groups but especially in the fixed dose combination group: for antiplatelet treatment it was 93% fixed dose combination v 83% usual care (P<0.001), for statin 94% v 89% (P=0.06), for combination blood pressure lowering 89% v 59% (P<0.001), and for any blood pressure lowering 96% v 91% (P=0.02). ...The number of participants with cardiovascular events or serious adverse events was similar in both treatment groups (fixed dose combination 16 v usual care 18 (P=0.73), 99 v 93 (P=0.56), respectively). ...
Adherence for each drug type at 12 months was high in both groups but especially in the fixed dose combination group: for antiplatelet treat …
Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand.
Elley CR, Kenealy T, Robinson E, Bramley D, Selak V, Drury PL, Kerse N, Pearson J, Lay-Yee R, Arroll B. Elley CR, et al. Among authors: Selak V. Diabetes Res Clin Pract. 2008 Mar;79(3):468-73. doi: 10.1016/j.diabres.2007.09.018. Epub 2007 Nov 19. Diabetes Res Clin Pract. 2008. PMID: 18022272
41 results
Jump to page
Feedback